Analysts Reassess Tech Names Ahead of Earnings

Hewlett Packard Enterprise is accelerating its push into artificial intelligence infrastructure as it approaches its Q1 2026 earnings release on March 9. The company has launched new networking and computing solutions intended to help service providers handle modern AI workloads.

A central element is the deeper integration of Juniper Networks’ technology, including newly unveiled modular routers designed to scale for AI and cloud data traffic. These routers feature very high port density and aim to maintain low latency as data volumes rise.

HPE is also rolling out next-generation servers with higher bandwidth and more compute cores, targeting demanding 5G and AI deployments. The company’s goal is to support “AI-native” networks capable of proactive problem-solving to safeguard service quality for AI applications.

Alongside product launches, HPE has created a new global leadership role focused on the hybrid cloud channel, seeking to improve sales execution and partner collaboration across its hybrid offerings. This comes as telecom operators and enterprises look to use AI for efficiency and new services.

Investors are watching whether these initiatives will translate into improved financial performance. HPE’s shares have fallen about 14% since the start of the year, trading at 17.66 euros, below a 52-week high of 22.70 euros, despite beating profit expectations in the prior quarter.

Best Buy currently carries an average “Hold” recommendation from 22 brokerages, with one “sell,” 14 “hold” and seven “buy” ratings. The average 12-month price target from covering analysts is about $79.79.

Recent research updates include Piper Sandler cutting its price target from $76 to $71 with a “neutral” rating, and Morgan Stanley (MS) trimming its objective from $82 to $76 while assigning an “equal weight” rating. Other firms such as BNP Paribas Exane, Telsey Advisory Group and Guggenheim have also issued neutral to positive views with targets between $68 and $95.

Separately, Wedbush on February 24 reduced its target price on Best Buy by 12.5% to $70 from $80, maintaining a Neutral stance ahead of Q4 FY 2026 results scheduled for March 3. The firm cited weak holiday sales and lingering memory supply shortages as key concerns.

Wedbush expects Q4 results to disappoint despite heavy discounting in consumer electronics, referencing U.S. December retail sales data that showed flat overall sales as households cut back on big-ticket purchases. It also warned that FY 2027 guidance could be pressured by continued memory supply issues and softer PC and electronics demand.

Wedbush now forecasts Best Buy same-store sales to decline in the low single digits for FY 2027, versus its earlier expectation of modest growth. Best Buy shares recently traded at $62.82, with a market capitalization of $13.16 billion and a 12‑month range of $54.99 to $90.86.

HP Inc. has received a consensus “Reduce” recommendation from 18 analysts, with six “sell,” ten “hold” and two “strong buy” ratings. The average one-year price target stands at $22.23.

Several banks have lowered targets in recent weeks. Citigroup cut its price objective from $22 to $20 with a “neutral” rating, while Goldman Sachs reduced its target from $21 to $16 and rated the stock “sell.” JPMorgan Chase and UBS have also moved targets down and maintained neutral stances.

HP shares opened at $18.83 on Friday, compared with a 52-week range between $17.56 and $33.90. The company recently reported quarterly EPS of $0.81, beating the $0.77 consensus, on revenue of $14.44 billion, up 6.9% year over year. HP’s net margin was 4.46%, and analysts expect 2026 EPS of 3.56.

HP issued Q2 2026 EPS guidance of $0.70 to $0.76 and announced a quarterly dividend of $0.30 per share, implying an annualized $1.20 and a yield of 6.4% at the latest share price. The dividend payout ratio stands at 45.45%.

Institutional investors hold about 77.53% of HP shares, with several large asset managers significantly increasing their positions in recent quarters. Insiders have sold 91,969 shares valued at $2.28 million over the last three months.

Biogen has an average “Hold” rating from 27 covering brokerages, with 15 “hold” and 12 “buy” recommendations. The average 12‑month target price is about $205.04.

Following Biogen’s latest results, several firms raised their targets. Royal Bank of Canada lifted its objective from $217 to $233 with an “outperform” rating, while Citigroup increased its target from $185 to $215 and kept a “neutral” view. Other brokers, including Wedbush and Piper Sandler, also nudged targets higher with neutral ratings.

Biogen recently reported quarterly EPS of $1.99, ahead of the $1.61 consensus, on revenue of $2.28 billion, slightly above expectations but down 7.2% year on year. Net margin was 13.07%, and return on equity reached 12.64%.

The company has guided for FY 2026 EPS of $15.25 to $16.25, and analysts on average forecast EPS of 15.83. Biogen shares opened at $188.02, within a 12‑month range of $110.04 to $202.41, and trade at a price-to-earnings ratio of 21.34.

Insiders hold 0.18% of Biogen stock, and institutional investors own 87.93%. A recent insider transaction saw Priya Singhal sell 2,660 shares at an average price of $199.83, reducing her position by 24.85% to 8,043 shares.